

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
to a collection of information unless it contains a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

Application Number	10/040,547
Filing Date	January 4, 2002
First Named Inventor	BLOOD, Christine H.
Group Art Unit	1653
Examiner Name	
Attorney Docket Number	70025-04-CIP

(use as many sheets as necessary)

Sheet 1 of

Attorney Docket Number	70025-04-CIP
------------------------	--------------

U.S. PATENT DOCUMENTS

~~RECEIVED~~

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

9/20/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box

+

PTO/SB/08B (10-96)

Approved for use through 10-31-99. OMB 0651-003

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no

persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		COMPLETE IF KNOWN	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/040,547
		Filing Date	January 4, 2002
		First Named Inventor	BLOOD, Christine
		Group Art Unit	1653
		Examiner Name	
Sheet 1 of 1	Attorney Docket Number	70025	APR 04 2 2002

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

TECH CENTER 1800/2900

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
CTK		Bednarek M.A. et al., "Structure-function studies on the cyclic peptide MT-II, lactam derivative of α -melanotropin," <i>Peptides</i> , Vol. 20:401-09 (1999)	
		Hadley M.E. et al., "Melanocortin Receptors: Identification and Characterization by Melanotropic Peptide Agonists and Antagonists," <i>Pigment Cell Res</i> , Vol. 9:213-34 (1996)	
		Haskell-Luevano C. et al., "Discovery of Prototype Peptidomimetic Agonists at the Human Melanocortin Receptors MC1R and MC4R," <i>Journal of Medical Chemistry</i> , Vol. 40:2133-39 (1997)	
		Hruby, V.J., et al., "Cyclic Lactam α -melanocyte-stimulating Hormone-(4-10)-NH ₂ with bulky aromatic amino acids at position 7 show high antagonist potency and selectivity at specific melanocortin receptors," <i>Journal of Medicinal Chemistry</i> , Vol. 38, No. 18: 3454-61 (1995)	
		Schiöth H.B. et al., "Discovery of novel melanocortin ₄ receptor selective MSH analogues," <i>British Journal of Pharmacology</i> , Vol. 124:75-82 (1998)	
		Schiöth H.B. et al., "Selective properties of C- and N-terminals and core residues of the melanocyte-stimulating hormone on binding to the human melanocortin receptor subtypes," <i>European Journal of Pharmacology</i> , Vol. 349:359-66 (1998)	
CTK		Wessells H. et al., "Synthetic Melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study," <i>Journal of Urology</i> , Vol. 160:389-393 (1998)	
		<u>Metabolism of Brain Peptides</u> , Ed. G. O'Cuinn, CRC Press, New York, 1995, pp. 1-9 and 99-101	

Examiner Signature		Date Considered	2/20/03
--------------------	--	-----------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[F:\MIKE\PATENT\IDS\Palatin\Sex Dysfunction 1449form-2-2.pat.doc]

¹ Unique citation designation number. 2. Applicant is to place a check mark here if English language Translation is attached.

+

+

OIPE
 AUG 07 2003
 TRADEMARK OFFICE

Application Number	10/040,547
Filing Date	January 4, 2002
First Named Inventor	BLOOD, Christine
Group Art Unit	1653
Examiner Name	C. Kam
Attorney Docket Number	70025-04-CIP

[illegible]

FOREIGN PATENT DOCUMENTS							
Examiner Initials	Cite No.1	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Whole Relevant Passages or Relevant Figures Abstract	To
		Office ³	Number ⁴				
CHK		FR	2 691 465		Fabre Medicament	11-26-1993	English abstract
CHK		FR	2 735 131		Societe D'Etude et de Recherche de Pathologie Applique	12-13-1996	English abstract
					Serpa Societa Civile		
CHK		PCT	WO 94/22460		Univ. Patents, Inc.	10-13-1994	

9/22/08

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**

